LORCET-HD
Clinical safety rating: caution
Comprehensive clinical and safety monograph for LORCET-HD (LORCET-HD).
Hydrocodone is a mu-opioid receptor agonist, modulating pain perception and emotional response to pain. Acetaminophen inhibits cyclooxygenase (COX) and modulates descending serotonergic pathways, providing antipyretic and analgesic effects.
| Metabolism | Hydrocodone is metabolized primarily by CYP3A4 and CYP2D6 to hydromorphone and other metabolites. Acetaminophen is metabolized by CYP2E1, CYP1A2, CYP3A4, and glucuronidation/sulfation. |
| Excretion | Renal: 90% as morphine-3-glucuronide and morphine-6-glucuronide, 10% as unchanged morphine; biliary: minor (<5%); fecal: <5%. |
| Half-life | Morphine: 2-4 hours; hydrocodone: 3.8-6 hours. Clinical context: Immediate-release, dosing every 4-6 hours. |
| Protein binding | Morphine: 30-35% bound to albumin; hydrocodone: ~50% bound to albumin. |
| Volume of Distribution | Morphine: 3-5 L/kg; hydrocodone: 4-5 L/kg. Indicates extensive tissue distribution. |
| Bioavailability | Oral: 20-40% (first-pass metabolism); rectal: similar. |
| Onset of Action | Oral: 10-30 minutes; peak effect at 30-60 minutes. |
| Duration of Action | 4-6 hours; extended with hepatic/renal impairment. |
1-2 tablets (hydrocodone 5-10 mg / acetaminophen 325-650 mg) orally every 4-6 hours as needed for pain; maximum acetaminophen 4 g/day (or 3 g/day in at-risk patients).
| Dosage form | CAPSULE |
| Renal impairment | eGFR < 30 mL/min: consider dose reduction or alternate therapy; hydrocodone accumulation risk. For severe renal impairment, avoid or use with extreme caution; initial dose reduction of 25-50% recommended. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% or extend interval; Child-Pugh C: contraindicated due to acetaminophen hepatotoxicity. |
| Pediatric use | Not FDA-approved for children <18 years. For weight-based dosing (if clinically justified): hydrocodone 0.1-0.2 mg/kg/dose orally every 4-6 hours; maximum single dose 10 mg; acetaminophen component not to exceed 75 mg/kg/day. |
| Geriatric use | Start with lowest effective dose (e.g., 1 tablet every 6 hours); monitor for respiratory depression, constipation, and cognitive impairment. Avoid in frail elderly; consider acetaminophen dose cap at 3 g/day. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for LORCET-HD (LORCET-HD).
| Breastfeeding | Hydrocodone passes into breast milk; M/P ratio is approximately 1.6. Acetaminophen also excreted into milk. Monitor infant for respiratory depression and sedation; consider benefit versus risk. American Academy of Pediatrics considers acetaminophen compatible with breastfeeding; hydrocodone use caution. |
| Teratogenic Risk | Acetaminophen is generally considered safe at therapeutic doses; chronic high doses may be associated with adverse fetal outcomes. Hydrocodone is classified as FDA Pregnancy Category C; risk of neonatal opioid withdrawal syndrome (NOWS) with prolonged use during third trimester. Use in first trimester may be associated with neural tube defects, though data are limited. |
■ FDA Black Box Warning
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion (especially in children) can be fatal; neonatal opioid withdrawal syndrome with prolonged use; risks from concomitant use with benzodiazepines or other CNS depressants (additive respiratory depression); Cytochrome P450 3A4 interaction with drugs affecting CYP3A4 may alter hydrocodone metabolism and increase risk of adverse effects.
| Serious Effects |
Significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment; known or suspected gastrointestinal obstruction, including paralytic ileus; hypersensitivity to hydrocodone, acetaminophen, or any component of the product; concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days of such therapy; severe hepatic impairment or active liver disease (relative, due to acetaminophen).
| Precautions | Serotonin syndrome with serotonergic drugs; adrenal insufficiency; hypotension; head injury or increased intracranial pressure; seizure threshold; severe hepatic injury from acetaminophen (dose-dependent); use in patients with hepatic impairment; use in patients with pulmonary disease; use in elderly, cachectic, or debilitated patients; opioid-induced hyperalgesia; severe hypotension; use in patients with biliary tract disease; pancreatitis; use in patients with renal impairment; use in patients with suicidal ideation; drug abuse history; driving and operating machinery. |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood pressure, heart rate, and respiratory status. Assess for signs of opioid withdrawal or toxicity. Fetal monitoring for growth and well-being if prolonged use; assess for NOWS in newborn. |
| Fertility Effects | Opioids may suppress gonadotropin-releasing hormone, leading to decreased libido, oligomenorrhea, or anovulation. Acetaminophen has no known significant effect on fertility. |